Thermo Fisher Scientific (NYSE:TMO) just crushed expectations, sending its stock up 6.6% this morning as investors cheered a strong Q4 and an even stronger outlook for 2025. Revenue jumped 5% to $11.40 billion, while adjusted EPS climbed 8% to $6.10, beating Wall Street estimates. The company's analytical instruments division led the charge, boosted by new product launches like the iCAP MX Series ICP-MS and Gibco CTS Detachable Dynabeads. Despite flat full-year revenue at $42.88 billion, Thermo Fisher made big movesacquiring Olink, returning $4.6 billion to shareholders, and strengthening its position as the go-to name in life sciences.
Investors are now eyeing what's next. Thermo Fisher projects 2025 adjusted EPS between $23.10 and $23.50, topping expectations. With interest rate cuts easing funding pressure, biotech clients could ramp up spending, giving Thermo Fisher another tailwind. Still, not everyone's convincedDanaher (NYSE:DHR) flagged ongoing caution among smaller biotech firms, though Sartorius (SATG.DE) reported a 23.1% jump in Q4 orders, suggesting demand is picking up. The bigger question: Will this momentum hold, or are we in for some turbulence?
CEO Marc Casper isn't worried. He sees 2025 as a year of growth, fueled by market share gains and deepening partnerships. With $29.06 billion in long-term obligations, Thermo Fisher has to balance aggressive expansion with financial discipline. But if the company executes like it did in Q4, investors betting on its continued dominance might have plenty to look forward to.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。